Compare KRP & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | CERT |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2017 | 2020 |
| Metric | KRP | CERT |
|---|---|---|
| Price | $14.11 | $10.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $19.20 | $12.68 |
| AVG Volume (30 Days) | 803.2K | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 11.09% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $333,830,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $21.85 | N/A |
| Revenue Next Year | $4.33 | $3.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.93 | ★ 8.75 |
| 52 Week Low | $11.31 | $4.45 |
| 52 Week High | $17.12 | $12.61 |
| Indicator | KRP | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 28.42 | 47.70 |
| Support Level | N/A | $6.26 |
| Resistance Level | $15.06 | $11.73 |
| Average True Range (ATR) | 0.42 | 0.63 |
| MACD | -0.22 | -0.17 |
| Stochastic Oscillator | 0.91 | 11.87 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.